Leptospirosis criteria

Jump to navigation Jump to search

Leptospirosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Leptospirosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Leptospirosis criteria On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Leptospirosis criteria

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Leptospirosis criteria

CDC on Leptospirosis criteria

Leptospirosis criteria in the news

Blogs on Leptospirosis criteria

Directions to Hospitals Treating Leptospirosis

Risk calculators and risk factors for Leptospirosis criteria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Clinical Criteria

An illness characterized by fever, headache, and myalgia, and less frequently by conjunctival suffusion, meningitis, rash, jaundice, or renal insufficiency. Symptoms may be biphasic.

Clinical presentation includes history of fever within the past two weeks and at least two of the following clinical findings: myalgia, headache, jaundice, conjunctival suffusion without purulent discharge, or rash (i.e. maculopapular or petechial); ORat least one of the following clinical findings:

Laboratory Criteria for Diagnosis

Diagnostic testing should be requested for patients in whom there is a high index of suspicion for leptospirosis, based either on signs and symptoms, or on occupational, recreational or vocational exposure to animals or environments contaminated with animal urine.

Supportive:

  • Leptospira agglutination titer of ≥ 200 but < 800 by Microscopic Agglutination Test (MAT) in one or more serum specimens, or
  • Demonstration of anti-Leptospira antibodies in a clinical specimen by indirect immunofluorescence, or
  • Demonstration of Leptospira in a clinical specimen by darkfield microscopy, or
  • Detection of IgM antibodies against Leptospira in an in acute phase serum specimen.

Confirmed:

  • Isolation of Leptospira from a clinical specimen, or
  • Fourfold or greater increase in Leptospira agglutination titer between acute- and convalescent-phase serum specimens studied at the same laboratory, or
  • Demonstration of Leptospira in tissue by direct immunofluorescence, or
  • Leptospira agglutination titer of ≥ 800 by Microscopic Agglutination Test (MAT) in one or more serum specimens, or
  • Detection of pathogenic Leptospira DNA (e.g., by PCR) from a clinical specimen.

Epidemiologic Linkage

Involvement in an exposure event (e.g., adventure race, triathlon, flooding) with associated laboratory-confirmed cases.

Case Classification

Probable

A clinically compatible case with at least one of the following:

  • Involvement in an exposure event (e.g., adventure race, triathlon, flooding) with known associated cases, or
  • Presumptive laboratory findings, but without confirmatory laboratory evidence of Leptospira infection.

Confirmed

A case with confirmatory laboratory results, as listed above.

References